Arrowhead Stock Rockets 16% After Major Licensing Deal
Strategic Sarepta partnership and FDA filing position Arrowhead for a transformative leap in RNAi therapeutics
Sarepta deal with Arrowhead a ‘prudent move,’ says Leerink
After Sarepta (SRPT) announced a global licensing and collaboration agreement with Arrowhead (ARWR) that adds four clinical-stage siRNA assets
Arrowhead climbs after licensing deal with Sarepta
Arrowhead Pharmaceuticals (NASDAQ:ARWR) added ~21% in the premarket on Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ:SRPT) for various clinical and preclinical programs.
Sarepta Therapeutics, Arrowhead Pharmaceuticals Ink Collaboration, Licensing Deal
Sarepta Therapeutics and Arrowhead Pharmaceuticals said they have entered a licensing and collaboration agreement worth more than $1 billion. Sarepta will secure exclusive global rights to multiple programs for rare genetic diseases affecting muscles,
Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments
Sarepta Therapeutics (SRPT), the leader in precision genetic medicine for rare diseases announced an exclusive global licensing and
Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal
Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta Therapeutics.
TipRanks on MSN7h
Arrowhead price target lowered to $45 from $62 at Piper Sandler
Piper Sandler lowered the firm’s price target on Arrowhead (ARWR) to $45 from $62 and keeps an Overweight rating on the ...
Arrowhead Pharmaceuticals Eyes Future Growth with Strategic Deals
Arrowhead Pharmaceuticals, Inc. ( (ARWR) ) has released its Q4 earnings. Here is a breakdown of the information Arrowhead Pharmaceuticals, Inc.
Biggest stock movers Tuesday: PSTX, ARWR, KSS, ALEC, AMGN, EMBC, and more
Stock futures edged lower on Tuesday as sentiment took a hit after President-elect Donald Trump said he would raise tariffs ...
Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...
RBC Capital Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)
RBC Capital analyst Luca Issi maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report) yesterday and set a price target of ...
bovnews1d
Arrowhead Pharmaceuticals (ARWR) Soars with Strategic Deal: A Transformative Move for the Company
Arrowhead Pharmaceuticals is a biotechnology company focused on developing RNA interference (RNAi) therapeutics. Their proprietary platform, Targeted RNAi Molecule (TRiM™), allows them to target and ...
Arrowhead Pharma, Sarepta TX ink new gene therapy deal
Arrowhead Pharmaceuticals (ARWR) has secured a new partnership with Sarepta Therapeutics (SRPT). Under the terms of the deal, ...
Arrowhead Pharmaceuticals (ARWR) Scheduled to Post Quarterly Earnings on Tuesday
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) is scheduled to be posting its quarterly earnings results after the ...
news.stocktradersdaily6d
(ARWR) Pivots Trading Plans and Risk Controls
Check the time stamp on this data. Updated AI-Generated Signals for Arrowhead Pharmaceuticals Inc. (ARWR) available here: ...
A Look Ahead: Arrowhead Pharma's Earnings Forecast
Analysts estimate that Arrowhead Pharma will report an earnings per share (EPS) of $-1.05. The market awaits Arrowhead Pharma's announcement, with hopes high for news of surpassing estimates and ...
Yahoo Finance5d
Arrowhead Pharmaceuticals Inc. (ARWR): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts
In this article, we are going to take a look at where Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) stands against the other NASDAQ stocks. Potomac Wealth Advisors president Mark Avallone joined CNBC ...
Arrowhead Pharmaceuticals’ Potential Approval of Clozasiran Drives Buy Rating and $60 Price Target
Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), retaining the price ...